Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | CPT2 | P23786 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | SLC13A5 | Q86YT5 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | OXER1 | Q8TDS5 | 2/20 | 0.34 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.34 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30549467 | 0.90 | FFAR1 (0.41) | FFAR1CPT2TDP1OPRM1OPRL1 | |
| SCHEMBL25352790 | 0.90 | FFAR1 (0.41) | FFAR1CPT2TDP1OPRM1OPRL1 | |
| SCHEMBL26060198 | 0.90 | ALDH1A1 (0.39) | OPRM1OPRL1ALDH1A1OXER1LTB4R | |
| SCHEMBL26060197 | 0.90 | FFAR1 (0.45) | FFAR1CPT2TDP1OPRM1OPRL1 | |
| SCHEMBL25995695 | 0.88 | FFAR1 (0.43) | FFAR1CPT2TDP1OPRM1OPRL1 | |
| SCHEMBL25355544 | 0.85 | OPRM1 (0.44) | FFAR1OPRM1OPRL1ALDH1A1OXER1 | |
| SCHEMBL25350883 | 0.84 | FFAR1 (0.39) | FFAR1CPT2TDP1OPRM1OPRL1 | |
| SCHEMBL30549455 | 0.84 | FFAR1 (0.39) | FFAR1CPT2TDP1OPRM1OPRL1 | |
| SCHEMBL26060972 | 0.83 | OPRM1 (0.34) | OPRM1OPRL1ALDH1A1OXER1LTB4R | |
| SCHEMBL25995660 | 0.83 | FFAR1 (0.39) | FFAR1CPT2TDP1OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4281058-B1 | FUNCTIONALIZED LONG-CHAIN DICARBOXYLIC ACIDS, AND THEIR USE FOR TREATMENT OF KIDNEY DISEASES | ESPERVITA THERAPEUTICS INC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12396972-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| US-20240398737-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2024-12-05 | — | — | US | disclosed |
| US-11737995-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11730712-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730712-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11737995-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | AHR, PKD1, CFTR | FFAR1 68/4885CPT2 615/4885TDP1 4883/4885 |
| US-12396972-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | AHR, PKD1, CFTR | FFAR1 69/4885CPT2 592/4885TDP1 4884/4885 |
| US-11730712-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | CPT1A, PPARG, PC | FFAR1 41/4885CPT2 25/4885TDP1 4828/4885 |
| US-20240398737-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | AHR, PKD1, CFTR | FFAR1 69/4885CPT2 592/4885TDP1 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.